Narmac,

BETonMACE is still blinded. As stated in the news release, the BETonMACE cognition sub-group poster and oral presentation at CTAD and AAIC will:

"highlight the design and baseline characteristics of a prespecified substudy of cognition in elderly patients in the Company’s ongoing phase 3 BETonMACE clinical trial"

I expect it to similar to the BETonMACE CKD sub-study poster presented earlier this year at ERA-EDTA, except it will highlight the cognition, not CKD, sub-study design and patient baseline data. Baseline data is that data collected at the start of the trial prior to randomization to the placebo or apabetalone group.

BearDownAZ